Lifestyle

6 Ways the Middleman Between You and Your Medication Is Making Your Drugs More Expensive

By Curtis Jones · August 18, 2026

There’s a company between your doctor and your pharmacist that decides what you pay for your medication. You’ve probably never heard of it. It’s heard of you.

Pharmacy benefits managers — PBMs — are the invisible middlemen of the American healthcare system. Three companies — CVS Caremark, Express Scripts, and OptumRx — process prescriptions for more than 200 million Americans and control nearly 80% of the market. They decide which drugs your insurance covers, what you pay at the counter, and how much your pharmacy gets reimbursed. Here’s what they don’t want you to understand.

They profit from higher list prices — not lower ones. PBMs negotiate rebates from drug manufacturers in exchange for placing medications on preferred formulary lists. Those rebates are calculated as a percentage of the drug’s list price. The higher the list price, the larger the rebate, and the more the PBM earns. This creates a perverse incentive: PBMs benefit when drug prices go up, not down. The FTC found that this system artificially inflated the cost of insulin for years.

Your copay is based on the inflated price — not the negotiated price. When you pick up a prescription, your copay or coinsurance is typically calculated as a percentage of the list price — the one the PBM helped inflate. The rebate the PBM negotiated from the manufacturer doesn’t reduce what you pay at the counter. It goes to the PBM and, in some cases, to your insurer. You’re paying a percentage of a price that doesn’t reflect the drug’s actual cost.

They can steer you away from cheaper pharmacies. Some PBMs own their own mail-order pharmacies and specialty pharmacies. They may design formularies and copay structures that penalize you for filling prescriptions at an independent pharmacy and reward you for using their own. The pharmacy that’s cheapest for you may not be the pharmacy the PBM wants you to use.

Formulary changes can happen mid-year. The list of covered medications can change during your plan year. A drug that was covered in January may be moved to a higher cost tier — or removed entirely — in July. You find out when the pharmacist tells you the price changed. The PBM made that decision based on a rebate negotiation, not a clinical assessment of your needs.

Clawbacks take money from your pharmacist. PBMs reimburse pharmacies for the drugs they dispense — but the reimbursement rate is often set below the pharmacy’s actual cost. Then, after the transaction, the PBM may assess additional fees — called direct and indirect remuneration (DIR) fees — that claw back a portion of the reimbursement. Independent pharmacies have described receiving payments that, after DIR fees, result in a net loss on the prescription. When pharmacies lose money dispensing your medication, they close. And when they close, you drive farther.

The $2,000 Medicare Part D cap doesn’t fix the underlying inflation. Starting in 2025, Medicare Part D out-of-pocket costs are capped at $2,000. That protects patients from catastrophic spending — but it doesn’t change the list prices, the rebate structure, or the PBM’s incentive to keep prices high. The cap shifts cost from the patient to the insurer, who passes it back through higher premiums. The system that created the problem is still in place.

The FTC has now sued all three major PBMs. The Caremark settlement this month could deliver up to $8.5 billion in consumer savings over a decade. But the structural incentives — rebates tied to list prices, vertical integration, and formulary control — remain. The company you’ve never heard of is still deciding what you pay.